-transparent.png){kind=logo}
Colorectal carcinoma patients' sera with ADCC antibody reacting with the HT-29 cell line (blood group A) generally (88%) cross-reacted with another group A cell line (COLO-394) but much less frequently (6-33%), with six tumor cell lines that did not express ABO blood group antigens. The findings suggested the possibility that the ADCC reactivity against the HT-29 cell line particularly by patients of blood group O is generally via "A" or "A-like" antigenicity of the target cells. This was supported by absorption studies that showed that the ADCC reactivity could be removed by blood group A but never by group B erythrocytes. Our results suggest that the prognostically favorable ADCC antibody in colorectal carcinoma patients' sera is of anti-blood group A specificity or cross reactivity.
S L Jones, and
E Pihl, and
A P Nind, and
P J Chalmers, and
R C Nairn
October 1974,
Journal of immunology (Baltimore, Md. : 1950),
S L Jones, and
E Pihl, and
A P Nind, and
P J Chalmers, and
R C Nairn
January 1999,
Methods in molecular medicine,
S L Jones, and
E Pihl, and
A P Nind, and
P J Chalmers, and
R C Nairn
January 2018,
Journal of theoretical biology,
S L Jones, and
E Pihl, and
A P Nind, and
P J Chalmers, and
R C Nairn
July 1977,
Orvosi hetilap,
S L Jones, and
E Pihl, and
A P Nind, and
P J Chalmers, and
R C Nairn
January 1981,
Reumatologia,
S L Jones, and
E Pihl, and
A P Nind, and
P J Chalmers, and
R C Nairn
June 1976,
Transplantation,
S L Jones, and
E Pihl, and
A P Nind, and
P J Chalmers, and
R C Nairn
February 1990,
Clinical immunology and immunopathology,
S L Jones, and
E Pihl, and
A P Nind, and
P J Chalmers, and
R C Nairn
January 1978,
Archivum immunologiae et therapiae experimentalis,
S L Jones, and
E Pihl, and
A P Nind, and
P J Chalmers, and
R C Nairn
January 1988,
Archivum immunologiae et therapiae experimentalis,
S L Jones, and
E Pihl, and
A P Nind, and
P J Chalmers, and
R C Nairn
January 1991,
Schweizer Archiv fur Neurologie und Psychiatrie (Zurich, Switzerland : 1985),
